Financial Performance - Revenue remained flat year-over-year at RMB6644 million[9,46] - Adjusted net profit decreased by 61% year-over-year to RMB1022 million, attributed to pricing decreases and marketing expenses[9,46] - Overseas sales increased by 40% year-over-year, reaching RMB1624 million, representing 244% of total sales[11,46] - R&D expenses reached RMB320 million, accounting for 47% of revenue[11] Business Segments - General medical device segment revenue was RMB3300 million, flat year-over-year, with a profit of RMB490 million, down by 171%[16] - Pharma packaging segment revenue was RMB1170 million, flat year-over-year, with a profit of RMB450 million, down by 58%[24] - Orthopaedics segment revenue was RMB730 million, slightly down by 16% year-over-year, but profit increased significantly by 743% to RMB150 million[27] - Blood management segment revenue increased by 81% year-over-year to RMB450 million, while profit decreased by 53% to RMB31 million[37] Strategic Initiatives - The company plans to maintain a dividend payout ratio at 50%[52] - Total production capacity for blood bags is expected to exceed 100 million units in 2025[37] - Auto injectors recorded strong sales in China, with H1 sales up by approximately 200%, accounting for approximately 3% of segment sales[24]